Sub-micrometer particle production by pressurised metered dose inhalers

M. Crampton, R. Kinnersley, Jonathan Geoffrey Ayres

    Research output: Contribution to journalArticle

    15 Citations (Scopus)

    Abstract

    Evidence from both the air pollution and inhaled aerosol therapy fields suggests that the physiological impact of fine and ultrafine aerosols (defined as those below 1000 and 100 nm aerodynamic diameter, respectively) may be greater than their mass or volume of active agent alone might suggest. Traditionally, Andersen impactors and liquid impingers have been used for the sizing of particles produced by pressurized metered dose inhalers (pMDIs). However, these fail adequately to size particles in the ultrafine range (< 100 nm aerodynamic diameter). In this paper, we report on a method of sizing pMDI particles down to 10 nm, using an electrical low pressure impactor (size range 30 nm to 10 mu m) and a scanning mobility particle sizer (size range 3-150 nm). A range of pMDI drug formulations were assessed, including Flixotide (HFA-fluticasone propionate, GSK [Glaxo Smith Klein%]) Salbulin (HFA-salbutamol sulphate, 3M), Qvar (HFA-beclomethasone dipropionate, 3M), Ventolin (HFA-salbutamol sulphate, GSK), Atrovent Forte (CFC-ipratropium bromide, Boehringer Ingelheim), Becotide (CFC-beclomethasone dipropionate, GSK), Pulmicort (CFC-budesonide, Astra Zeneca), and Serevent (CFC-Salmeterol xinafoate, GSK). All devices yielded high numbers of fine and ultrafine particles, with number median aerodynamic diameters (NMAD) of Qvar 68 nm, Becotide 73 nm, Salbulin 85 nm, and Pulmicort 89 nm, and %< 100 nm Qvar 76%, Becotide 65%, Salbulin 61%, and Pulmicort 60%. We found a general trend of HFA-propelled pMDIs to produce smaller particles than the CFC units, but this trend was not statistically significant. These findings support previous published work, which suggests that significant bioactivity of pMDIs may reside in the ultrafine fraction.

    Original languageEnglish
    Pages (from-to)33-42
    Number of pages9
    JournalJournal of Aerosol Science
    Volume17
    Issue number1
    DOIs
    Publication statusPublished - 2004

    Keywords

    • ULTRAFINE PARTICLES
    • LUNG INJURY
    • DELIVERY
    • AEROSIZER(R)
    • INHALATION
    • AEROSOLS

    Cite this

    Sub-micrometer particle production by pressurised metered dose inhalers. / Crampton, M.; Kinnersley, R.; Ayres, Jonathan Geoffrey.

    In: Journal of Aerosol Science, Vol. 17, No. 1, 2004, p. 33-42.

    Research output: Contribution to journalArticle

    Crampton, M. ; Kinnersley, R. ; Ayres, Jonathan Geoffrey. / Sub-micrometer particle production by pressurised metered dose inhalers. In: Journal of Aerosol Science. 2004 ; Vol. 17, No. 1. pp. 33-42.
    @article{8d0afa8f106b4f909708c14ab53abe0d,
    title = "Sub-micrometer particle production by pressurised metered dose inhalers",
    abstract = "Evidence from both the air pollution and inhaled aerosol therapy fields suggests that the physiological impact of fine and ultrafine aerosols (defined as those below 1000 and 100 nm aerodynamic diameter, respectively) may be greater than their mass or volume of active agent alone might suggest. Traditionally, Andersen impactors and liquid impingers have been used for the sizing of particles produced by pressurized metered dose inhalers (pMDIs). However, these fail adequately to size particles in the ultrafine range (< 100 nm aerodynamic diameter). In this paper, we report on a method of sizing pMDI particles down to 10 nm, using an electrical low pressure impactor (size range 30 nm to 10 mu m) and a scanning mobility particle sizer (size range 3-150 nm). A range of pMDI drug formulations were assessed, including Flixotide (HFA-fluticasone propionate, GSK [Glaxo Smith Klein{\%}]) Salbulin (HFA-salbutamol sulphate, 3M), Qvar (HFA-beclomethasone dipropionate, 3M), Ventolin (HFA-salbutamol sulphate, GSK), Atrovent Forte (CFC-ipratropium bromide, Boehringer Ingelheim), Becotide (CFC-beclomethasone dipropionate, GSK), Pulmicort (CFC-budesonide, Astra Zeneca), and Serevent (CFC-Salmeterol xinafoate, GSK). All devices yielded high numbers of fine and ultrafine particles, with number median aerodynamic diameters (NMAD) of Qvar 68 nm, Becotide 73 nm, Salbulin 85 nm, and Pulmicort 89 nm, and {\%}< 100 nm Qvar 76{\%}, Becotide 65{\%}, Salbulin 61{\%}, and Pulmicort 60{\%}. We found a general trend of HFA-propelled pMDIs to produce smaller particles than the CFC units, but this trend was not statistically significant. These findings support previous published work, which suggests that significant bioactivity of pMDIs may reside in the ultrafine fraction.",
    keywords = "ULTRAFINE PARTICLES, LUNG INJURY, DELIVERY, AEROSIZER(R), INHALATION, AEROSOLS",
    author = "M. Crampton and R. Kinnersley and Ayres, {Jonathan Geoffrey}",
    year = "2004",
    doi = "10.1089/089426804322994442",
    language = "English",
    volume = "17",
    pages = "33--42",
    journal = "Journal of Aerosol Science",
    issn = "0021-8502",
    publisher = "Elsevier Limited",
    number = "1",

    }

    TY - JOUR

    T1 - Sub-micrometer particle production by pressurised metered dose inhalers

    AU - Crampton, M.

    AU - Kinnersley, R.

    AU - Ayres, Jonathan Geoffrey

    PY - 2004

    Y1 - 2004

    N2 - Evidence from both the air pollution and inhaled aerosol therapy fields suggests that the physiological impact of fine and ultrafine aerosols (defined as those below 1000 and 100 nm aerodynamic diameter, respectively) may be greater than their mass or volume of active agent alone might suggest. Traditionally, Andersen impactors and liquid impingers have been used for the sizing of particles produced by pressurized metered dose inhalers (pMDIs). However, these fail adequately to size particles in the ultrafine range (< 100 nm aerodynamic diameter). In this paper, we report on a method of sizing pMDI particles down to 10 nm, using an electrical low pressure impactor (size range 30 nm to 10 mu m) and a scanning mobility particle sizer (size range 3-150 nm). A range of pMDI drug formulations were assessed, including Flixotide (HFA-fluticasone propionate, GSK [Glaxo Smith Klein%]) Salbulin (HFA-salbutamol sulphate, 3M), Qvar (HFA-beclomethasone dipropionate, 3M), Ventolin (HFA-salbutamol sulphate, GSK), Atrovent Forte (CFC-ipratropium bromide, Boehringer Ingelheim), Becotide (CFC-beclomethasone dipropionate, GSK), Pulmicort (CFC-budesonide, Astra Zeneca), and Serevent (CFC-Salmeterol xinafoate, GSK). All devices yielded high numbers of fine and ultrafine particles, with number median aerodynamic diameters (NMAD) of Qvar 68 nm, Becotide 73 nm, Salbulin 85 nm, and Pulmicort 89 nm, and %< 100 nm Qvar 76%, Becotide 65%, Salbulin 61%, and Pulmicort 60%. We found a general trend of HFA-propelled pMDIs to produce smaller particles than the CFC units, but this trend was not statistically significant. These findings support previous published work, which suggests that significant bioactivity of pMDIs may reside in the ultrafine fraction.

    AB - Evidence from both the air pollution and inhaled aerosol therapy fields suggests that the physiological impact of fine and ultrafine aerosols (defined as those below 1000 and 100 nm aerodynamic diameter, respectively) may be greater than their mass or volume of active agent alone might suggest. Traditionally, Andersen impactors and liquid impingers have been used for the sizing of particles produced by pressurized metered dose inhalers (pMDIs). However, these fail adequately to size particles in the ultrafine range (< 100 nm aerodynamic diameter). In this paper, we report on a method of sizing pMDI particles down to 10 nm, using an electrical low pressure impactor (size range 30 nm to 10 mu m) and a scanning mobility particle sizer (size range 3-150 nm). A range of pMDI drug formulations were assessed, including Flixotide (HFA-fluticasone propionate, GSK [Glaxo Smith Klein%]) Salbulin (HFA-salbutamol sulphate, 3M), Qvar (HFA-beclomethasone dipropionate, 3M), Ventolin (HFA-salbutamol sulphate, GSK), Atrovent Forte (CFC-ipratropium bromide, Boehringer Ingelheim), Becotide (CFC-beclomethasone dipropionate, GSK), Pulmicort (CFC-budesonide, Astra Zeneca), and Serevent (CFC-Salmeterol xinafoate, GSK). All devices yielded high numbers of fine and ultrafine particles, with number median aerodynamic diameters (NMAD) of Qvar 68 nm, Becotide 73 nm, Salbulin 85 nm, and Pulmicort 89 nm, and %< 100 nm Qvar 76%, Becotide 65%, Salbulin 61%, and Pulmicort 60%. We found a general trend of HFA-propelled pMDIs to produce smaller particles than the CFC units, but this trend was not statistically significant. These findings support previous published work, which suggests that significant bioactivity of pMDIs may reside in the ultrafine fraction.

    KW - ULTRAFINE PARTICLES

    KW - LUNG INJURY

    KW - DELIVERY

    KW - AEROSIZER(R)

    KW - INHALATION

    KW - AEROSOLS

    U2 - 10.1089/089426804322994442

    DO - 10.1089/089426804322994442

    M3 - Article

    VL - 17

    SP - 33

    EP - 42

    JO - Journal of Aerosol Science

    JF - Journal of Aerosol Science

    SN - 0021-8502

    IS - 1

    ER -